Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/100160
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKillick, Emma-
dc.contributor.authorMorgan, Richard-
dc.contributor.authorLaunchbury, Francesca-
dc.contributor.authorBancroft, Elizabeth K.-
dc.contributor.authorPage, Elizabeth-
dc.contributor.authorCastro, Elena-
dc.contributor.authorKote-Jarai, Zsofia-
dc.contributor.authorAprikian, Armen-
dc.contributor.authorBlanco Guillermo, Ignacio-
dc.contributor.authorClowes, Virginia-
dc.contributor.authorDomchek, Susan M.-
dc.contributor.authorDouglas, Fiona-
dc.contributor.authorEccles, Diana-
dc.contributor.authorEvans, D. Gareth-
dc.contributor.authorHarris, Marion-
dc.contributor.authorKirk, Judy-
dc.contributor.authorLam, Jimmy-
dc.contributor.authorLindeman, Geoffrey J.-
dc.contributor.authorMitchell, Gillian-
dc.contributor.authorPachter, Nicholas-
dc.contributor.authorSelkirk, Christina-
dc.contributor.authorTucker, Kathy-
dc.contributor.authorZgajnar, Janaz-
dc.contributor.authorEeles, Rosalind A.-
dc.contributor.authorPandha, Hardev-
dc.date.accessioned2016-07-06T08:12:18Z-
dc.date.available2016-07-06T08:12:18Z-
dc.date.issued2013-06-24-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/2445/100160-
dc.description.abstractControversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.-
dc.format.extent5 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherNature Publishing Group-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1038/srep02059-
dc.relation.ispartofScientific Reports, 2013, vol. 3, p. 2059-
dc.relation.urihttp://dx.doi.org/10.1038/srep02059-
dc.rightscc-by-nc-nd (c) Killick, Emma et al., 2013-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationCàncer de pròstata-
dc.subject.classificationFactors de risc en les malalties-
dc.subject.classificationMarcadors tumorals-
dc.subject.classificationAntigen específic de la pròstata-
dc.subject.otherProstate cancer-
dc.subject.otherRisk factors in diseases-
dc.subject.otherTumor markers-
dc.subject.otherProstate-specific antigen-
dc.titleRole of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec639620-
dc.date.updated2016-07-06T08:12:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid23792811-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
639620.pdf282.06 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons